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Abstract
Background and objectives Fostamatinib is a spleen tyr-
osine kinase inhibitor that has been investigated as therapy
for rheumatoid arthritis and immune thrombocytopenic
purpura. The present studies assessed the potential for
pharmacokinetic interaction between fostamatinib and the
commonly prescribed medications oral contraceptive (OC),
warfarin, and statins (rosuvastatin, simvastatin) in healthy
subjects.
Methods The OC study was a crossover study over two
28-day treatment periods (Microgynon 30 plus placebo or
fostamatinib). Concentrations of OC constituents (ethinyl
estradiol/levonorgestrel) were measured. Effects on war-
farin pharmacokinetics and pharmacodynamics were
assessed (21-day study). Warfarin was administered on
days 1 and 14, fostamatinib on days 8–20. The statin study
was a two-period, fixed-sequence study of the effects of
fostamatinib on exposure to rosuvastatin or simvastatin
(single doses). Safety was assessed throughout.
Results Fostamatinib co-administration with OC
increased exposure to ethinyl estradiol [area under the
plasma concentration–time curve at steady state (AUCss)
28 % [confidence interval (CI 90 %) 21–36]; maximum
plasma concentration (Cmax) at steady state (Cmax,ss) 34 %
(CI 26–43)], but not levonorgestrel (AUCss 5 %; Cmax,ss
-3 %), while exposure to luteinizing hormone and follicle-
stimulating hormone decreased (&20 %). Fostamatinib did
not affect the pharmacokinetics/pharmacodynamics of
warfarin to a clinically relevant extent, but caused an
upward trend in AUC for both R- and S-warfarin [18 % (CI
13–23) and 13 % (CI 7–19)]. Fostamatinib increased
rosuvastatin AUC by 96 % (CI 78–115) and Cmax by 88 %
(CI 69–110), and increased simvastatin acid AUC by 74 %
(CI 50–102) and Cmax by 83 % (CI 57–113).
Conclusion Fostamatinib exhibits drug–drug interactions
when co-administered with OC, simvastatin, or rosuvas-
tatin, with the AUC of statins almost doubling. Fostama-
tinib did not exhibit a clinically relevant DDI on warfarin.
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AUCss Area under the plasma concentration–time
curve during the dosing interval at steady
state
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Fostamatinib is an orally dosed inhibitor of spleen tyrosine
kinase [1]. It has been investigated in patients with
rheumatoid arthritis (RA) [2–6], and is currently under
development for immune thrombocytopenic purpura [7, 8]
and immunoglobulin A nephropathy [9].
The metabolism of fostamatinib involves dephosphory-
lation of the prodrug (R788) in the gastrointestinal tract to
produce the active metabolite, R406 [1]. Understanding the
pharmacologic interactions of fostamatinib and R406 is
important when considering other commonly reported co-
morbidities in patients with RA (e.g., dyslipidemia and
cardiovascular disease [10–12]. Polypharmacy is common
in these individuals, predisposing them to drug–drug
interactions [13]. We present three studies that investigated
the influence of fostamatinib co-administration on the
pharmacokinetics of oral contraceptive (OC), warfarin, and
the 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA)
reductase inhibitors rosuvastatin and simvastatin.
Fostamatinib is metabolized by cytochrome P450 3A4
(CYP3A4), which it also inhibits in a time-dependent
manner [1]. CYP3A4 is involved in the metabolism of OC.
Fostamatinib is a substrate and inhibitor of uridine 50-
diphospho-glucuronosyltransferase (UGT), which is
involved in the glucuronidation of estradiol [14]. RA is
common in pre-menopausal women [15, 16]. Therefore,
our first study anticipated that co-administration of fosta-
matinib with an OC [Microgynon 30 (ethinyl estradiol
and levonorgestrel; Bayer Pharma AG, Berlin, Germany)]
would increase plasma ethinyl estradiol concentrations.
We also investigated the effects of fostamatinib on the
pharmacokinetics of warfarin, an anticoagulant that is
administered as a racemic mixture comprising equal
amounts of R- and S-warfarin [17, 18]. S-warfarin is a
substrate of CYP2C9, and R-warfarin for CYP1A2,
CYP2C19, and CYP3A4 [19]. Fostamatinib does not
induce CYP1A2, CYP2C9, CYP2C19, or CYP3A4 [1], and
therefore it was expected that fostamatinib would not
reduce plasma warfarin concentrations or activity. How-
ever, due to the narrow therapeutic index of warfarin and
its widespread use, it was important to confirm this
experimentally.
Finally, we investigated the influence of fostamatinib on
the pharmacokinetics of rosuvastatin and simvastatin.
These statins are used to improve lipid profiles in patients
at high risk for cardiovascular disease [20–22]. Rosuvas-
tatin is a substrate of active transporters, including both
organic anion-transporting polypeptide (OATP) 1B1 and
breast cancer resistance protein (BCRP) [23–25], while
simvastatin is metabolized by CYP3A4 and is a substrate
of OATP1B1 [26, 27]. In vitro data show that both fosta-
matinib and R406 are potent inhibitors of BCRP [half
maximal inhibitory concentration (IC50) 0.050 lmol/L and
0.031 lmol/L, respectively (AstraZeneca, data on file)].
R406 is a low-affinity substrate and weak inhibitor of
OATP1B1 [IC50 estimated at [10 lmol/L (AstraZeneca,
data on file)]. Current US Food and Drug Administration
guidance [28] predicts that fostamatinib would increase
systemic exposure to rosuvastatin through its inhibition of
intestinal BCRP (theoretical gastrointestinal concentration/
IC50[10), rather than via OATP1B1, resulting in increased
absorption.
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2 Methods
2.1 Subject Populations
All three studies (NCT01276262, NCT01311622, and
NCT01725230) were performed in accordance with the
principles of the Declaration of Helsinki [29] and the
International Conference on Harmonisation/Good Clinical
Practice [30]. All subjects gave written informed consent.
Protocols for the OC and warfarin studies were reviewed
by Capenhurst Independent Ethics Committee and the
statin study by MidLands IRB.
The studies included healthy subjects aged C18 years
and with a body mass index of C18 kg/m2. Subjects in the
OC study had to be willing to use highly effective non-
hormonal birth control such as double-barrier method
contraception. Detailed inclusion and exclusion criteria are
described in the Electronic Supplementary Material (On-
line Resource 1).
2.2 Study Objectives
The primary objective of the OC study was to assess the effect
of repeated doses of fostamatinib on the pharmacokinetics of
Microgynon 30 by assessment of its constituents, ethinyl
estradiol and levonorgestrel, on day 21. Secondary objectives
were to characterize the pharmacodynamics of progesterone,
luteinizing hormone (LH), follicle-stimulating hormone
(FSH), and sex hormone-binding globulin (SHBG) following
dosing with Microgynon 30 alone and following co-admin-
istration with fostamatinib. For the warfarin study (warfarin
supplied by Goldshield, Croydon, UK), the primary objective
was to investigate whether R- and S-warfarin plasma concen-
tration–time profiles and resulting pharmacokinetic parame-
ters (single administration) are altered during steady-state
fostamatinib administration. This study also investigated the
international normalized ratio (INR) after a warfarin admin-
istration, alone and with fostamatinib co-administration. The
main objectives of the statin study were to assess the phar-
macokinetics of rosuvastatin (AstraZeneca Pharmaceuticals
LP, Wilmington, DE, USA) and simvastatin (Merck Sharp &
Dohme Ltd., Whitehouse Station, NJ, USA) when each was
administered alone and in combination with fostamatinib.
Each study also evaluated the steady-state pharmacoki-
netics of the active metabolite R406 following co-admin-
istration of the respective investigational drugs with
fostamatinib. Safety and tolerability of fostamatinib in
combination with each drug were also examined.
2.3 Study Design
The OC study was a phase I, single-blind, placebo-con-
trolled, two-period, fixed-sequence, crossover study that
consisted of a B35-day screening period followed by two
treatment periods (28 days each) of Microgynon 30
(1 tablet/day comprising 30 lg ethinyl estradiol and
150 lg levonorgestrel) in the absence (treatment A =
OC ? placebo) and presence (treatment B = OC ? fos-
tamatinib) of fostamatinib [100 mg twice daily (bid)]
(Fig. 1a). The warfarin study was an open-label, non-ran-
domized study during which warfarin 25 mg was
administered on days 1 and 14 of a 20-day treatment
period along with fostamatinib 100 mg bid on days 8–20
(Fig. 1b). The statin study was an open-label, fixed-se-
quence study that assigned eligible subjects to receive
either rosuvastatin 20 mg (group A) or simvastatin 40 mg
(group B) over two treatment periods: alone for period 1
and in combination with fostamatinib (100 mg bid) for
period 2 (Fig. 1c).
2.3.1 Sample Collection and Bioanalysis
For each period in the OC study, serial blood samples for
pharmacokinetic analyses were collected before dose and
periodically after dose, relative to OC administration on
day 21. In the warfarin study, pharmacokinetic and phar-
macodynamic samples were collected before dose and
periodically after dose relative to days 1 and 14. For the
statin study, blood samples were collected before dose and
periodically after dose relative to day 1 in period 1 and
day 6 in period 2. Details for sample collection in each
study can be found in the Electronic Supplementary
Material. In the statin study blood samples were taken
from all subjects to collect DNA for extraction and
investigation of variations in the genes encoding BCRP
and OATP1B1 transporters, which are involved in rosu-
vastatin disposition.
All assays for R406, ethinyl estradiol, levonorgestrel, R-
and S-warfarin, rosuvastatin, simvastatin, and simvastatin
acid used deuterated internal standards and were analyzed
by liquid chromatography (LC) with tandem mass spec-
trometric detection (MS/MS).
Ethinyl estradiol and levonorgestrel were analyzed in
human plasma with K2EDTA anticoagulant.
The analytes were extracted with 1-chlorobutane. The
organic phase was decanted and evaporated to dryness. The
residue was derivatized with dansyl chloride and analyzed.
The standard curve range was 7.50–500 pg/mL for ethinyl
estradiol and 150–10,000 pg/mL for levonorgestrel for a
0.5 mL sample volume. LC analysis used a Phenomenex
Onyx Monolithic C18 column, with a gradient mobile
phase system (mobile phase A: 0.1 % formic acid in water;
mobile phase B: acetonitrile). Detection was by a Sciex
API 5000 or QTRAP 5500 (positive ion electrospray ion-
ization), with the transition monitored 530 ? 171 for
ethinyl estradiol and 313 ? 245 for levonorgestrel.
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Fig. 1 Study designs for a OC interaction study, b warfarin inter-
action study, and c statin interaction study. Asterisks Stabilization
period: those already taking Microgynon 30 continued taking it for
at least 21 days from screening to day -1 of period 1. Those not
already taking Microgynon 30 started it after screening and
continued for three stabilization cycles of at least 21 days. The last
stabilization cycle could be extended up to a maximum of 49 days,
for the purpose of synchronizing the cycles of healthy subjects so that
they would participate in the study in groups. Bid twice daily, OC oral
contraceptive
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The R- and S-warfarin method was used to analyze
human plasma with sodium EDTA or lithium heparin
anticoagulant. Samples were extracted by liquid–liquid
extraction. After evaporation, the residue was reconstituted
and analyzed. The standard curve range was 5–1500 ng/
mL for R- and S-warfarin, using a plasma sample volume
of 0.25 mL. The LC used an Alltech Phenomenex Astec b-
cyclodextrin Cyclobond I column with an isocratic mobile
phase system [acetonitrile:acetic acid:TEA (1000:3:2.5,
v:v:v)]. Detection was by a Sciex API 3000 or 4000
(negative ion APCI), with the transition monitored
307.1 ? 161.0 for R- and S-warfarin.
The simvastatin and simvastatin acid method was used
to analyze human plasma with sodium heparin or K2EDTA
anticoagulant. Samples were extracted by liquid–liquid
extraction. After evaporation under nitrogen, the residue
was reconstituted and analyzed. The standard curve range
was from 0.05 to 50 ng/mL for simvastatin and 0.05 to
10 ng/mL for simvastatin acid, using a sample volume of
0.250 mL. The LC used a Grace GenesisLightn C18 col-
umn with an isocratic mobile phase system [25 % mobile
phase A: (acetic acid 500 mM, pH 4.0): water (10:90);
75 % mobile phase B: acetonitrile] at a flow rate of
0.6 mL/min. Detection was by a Sciex API 5000, with the
transition monitored 419 ? 199 (positive ion electrospray
ionization) for simvastatin and 435 ? 319 (negative ion
electrospray ionization) for simvastatin acid.
The Rosuvastatin method was used to analyze buffered
human plasma treated with lithium heparin anticoagulant.
Samples were extracted by supported liquid extraction
(SLE). After evaporation, the residue was reconstituted and
analyzed. The standard curve range was from 0.02 to
20 ng/mL for rosuvastatin, using a human plasma sample
volume of 0.1 mL. The LC used a Thermo Electron Cor-
poration, Aquasil C18 column with a gradient mobile phase
system [mobile phase A: water: formic acid (100:0.1);
mobile phase B: acetonitrile: formic acid (100:0.1)].
Detection was by a Sciex API 5500 (positive ion electro-
spray ionization), with the transition monitored
482.2 ? 258.2 for rosuvastatin.
R406 was extracted from EDTA plasma using liquid–
liquid extraction with MTBE. The extracts were subse-
quently dried under Nitrogen, reconstituted and analysed
by LC-MS/MS. The LC method used a 0.1 % formic acid
water/acetonitrile gradient with a Chromolith SpeedROD
RP-18e analytical column. The mass spectrometer (Sciex
API 4000) used positive ion electrospray, monitoring the
transition 471/451 (the equivalent was monitored for the
deuterated internal standard). The analytical range was
2.50 ng/mL (LLOQ) to 2500 ng/mL. In the OC study, LH,
FSH and SHBG were analyzed using standard ELISA
methods at Quintiles Drug Research Unit at Guy’s
Hospital.
2.3.2 Pharmacokinetic Analyses
Pharmacokinetic parameters were determined by non-
compartmental analysis using WinNonlin version 5.2
(Pharsight Corp, Mountain View, CA, USA), with SAS
version 9.2 (SAS Institute Inc, Cary, NC, USA) and Sig-
maPlot version 9.0 (Systat Software Inc, San Jose, CA,
USA) also used in statistical analysis.
In the OC study, pharmacokinetic parameters calculated
for ethinyl estradiol and levonorgestrel included area under
the concentration–time curve from zero to tau at steady
state (AUCss) and the maximum plasma concentration at
steady state (Cmax,ss). The pharmacodynamic parameters
calculated for progesterone, LH, FSH, and SHBG were
AUCss, Cmax,ss, the minimum plasma concentration at
steady state, and the time to Cmax,ss (tmax,ss). Primary
variables in the warfarin study were AUC and Cmax for R-
and S-warfarin. Pharmacodynamic measurements for this
study were the maximum INR (INRmax) and the area under
the INR–time curve from zero to 168 h after dose
(AUCINR,0–168). In the statin study, the primary parameters
were AUC and Cmax for rosuvastatin and AUC from zero to
the time of the last measurable concentration (AUCt) and
Cmax for simvastatin acid. Pharmacokinetic parameters
calculated for R406 were AUCss, Cmax,ss, and tmax,ss in the
OC and warfarin studies, and AUC during a dosage interval
(s) (AUCs), Cmax, and tmax in the statin study.
2.3.3 Statistical Analyses
In all three studies, all subjects who received at least one
dose of investigational product were included in the safety
analysis set. All available data were included in the safety
analyses. The pharmacokinetic analysis set included only
subjects who received one or more doses of investigational
treatment and had one or more post-dose pharmacokinetic
measurements without important protocol deviations. No
adjustment or imputation was used for missing values, and
analyses were not restricted to subjects with complete
data.
A sample size of 28 subjects was estimated to provide
90 % power that a two-sided 90 % confidence interval (CI)
for the ratios of interest (Cmax,ss and AUCss for each ana-
lyte) of OC administered with fostamatinib to that of OC
alone would be completely contained within the pre-spec-
ified equivalence range of 0.80–1.25, if there is truly no
drug–drug interaction between OC and fostamatinib, based
on a two-sided 5 % significance test.
The intra-subject %CV of ethinyl estradiol was assumed
at 25 %. The intra-subject %CV for levonorgestrel was
assumed to be equal to or less than 25 %.
The warfarin study was not statistically powered in
terms of claiming no effect of fostamatinib on exposure to
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R- or S-warfarin (i.e., if the 90 % CI is within 0.80–1.25).
Interpretation of the results is based on the size of the
treatment ratio and associated 90 % CIs. To illustrate the
size of effect that could be detected, it was estimated that
12 subjects would provide approximately 84 % power to
detect a 50 % increase in AUC and Cmax, significant at the
5 % level. This was based on data from various warfarin
studies that suggested an approximate co-efficient of vari-
ation of 45 % for both AUC and Cmax. A warfarin coeffi-
cient of variation of 45 % was assumed for both AUC and
Cmax.
In the statin study, pharmacokinetic parameters were
analyzed using an analysis of variance model with fixed
effects for treatment and subject, following a natural log-
arithmic transformation. Although the primary pharma-
cokinetic variables for rosuvastatin and simvastatin were
AUC and Cmax, there were insufficient data to calculate
AUC for simvastatin acid without extensive extrapolation.
Therefore, AUCt was considered the primary pharma-
cokinetic variable in place of AUC for simvastatin acid
only. This study was not statistically powered in terms of
claiming no effect of fostamatinib on exposure to rosu-
vastatin or simvastatin. Interpretation of the results was
based on the size of the treatment ratio and associated 90 %
CI. To illustrate the size of effect that could be detected, it
was estimated that 18 completed subjects would provide
approximately 80 % power to detect a ratio of 1.27 or more
in AUC and Cmax, using a two-sided 5 % significance test.
Intra-subject CVs of 21 and 27 % for AUC and 34 and
38 % for Cmax were assumed for rosuvastatin and sim-
vastatin, respectively. It was pre-planned to use least
square mean data to summarise treatment exposure and to
compare exposure across treatments for all studies. This
was to accommodate the possibility that dropouts could
occur for one treatment leaving an imbalance in numbers.
In practice, there were no dropouts nor imbalance for some
analyses but the least mean square approach was carried
through so that it was not necessary to change the planned
analysis once the data were available. Since there was a
balance in n in some analyses the use of least squares
means will not have impacted on the results obtained
because mean and least squares mean give the same result
in this situation.
2.3.4 Safety Assessments
Safety and tolerability assessments included the incidence
and severity of adverse events (AEs), clinical laboratory
data, vital signs, 12-lead electrocardiograms, and physical
examinations. AEs were tabulated and summarized




Subject demographics and baseline characteristics for all
studies are shown in Table 1.
3.2 Pharmacokinetics
All assays for R406, ethinyl estradiol, levonorgestrel, R-
and S-warfarin, rosuvastatin, simvastatin, and simvastatin
acid performed reliably during the analyses.
In the OC study for the R406 analysis, precision (%CV)
and accuracy (% bias) for the QC samples at three con-
centrations were B10.1 % and within -4.0 to -0.8 %,
respectively. For the ethinyl estradiol analysis, precision
and accuracy for the QC samples at three concentrations
were B6.3 % and within -3.4 to 5.2 %, respectively. For
the levonorgestrel analysis, precision and accuracy for the
QC samples at three concentrations were B5.3 % and
within -2.8 to 7.2 %, respectively.
For the warfarin study for the R406 analysis, precision
and accuracy for the QC samples at three concentrations
were B7.6 % and within -4.0 to -0.9 %, respectively. For
the warfarin analysis, precision for the QC samples at three
concentrations was B5.3 % for R-warfarin and B5.5 % for
S-warfarin. Accuracy for the QC samples at three














Men, n (%) 0 14 (93.3) 20 (95.2) 21 (100)
Women,
n (%)
33 (100) 1 (6.7) 1 (4.8) 0
Age, years 26 37 33 (10) 33 (11)
Race
White 27 (81.8) 10 (66.7) 13 (61.9) 14 (66.7)




0 0 0 1 (4.8)












27.4 (3.5) 26.2 (2.8) 25.6 (2.7)
OC oral contraceptive, SD standard deviation
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concentrations was within -10.0 to -4.7 % for R-warfarin
and within -10.0 to -4.0 % for S-warfarin.
For the statin study for the R406 analysis, precision and
accuracy for the QC samples at three concentrations were
B5.1 % and within 6.8–9.5 %, respectively. For the sim-
vastatin analysis, precision for the QC samples at three
concentrations was B7.2 % for simvastatin and B5.8 % for
simvastatin acid. Accuracy for the QC samples at three
concentrations was within -9.1 to 2.0 % for simvastatin
and within 3.3–12.0 % for simvastatin acid. For the rosu-
vastatin analysis, precision and accuracy for the QC sam-
ples at three concentrations were B5.4 % and within -0.0
to 2.7 %, respectively.
3.2.1 OC Interaction Study
Thirty-three subjects were recruited and six discontinued
treatment.
Levonorgestrel concentrations were similar throughout
the dosing interval when OC was co-administered with
fostamatinib and when it was administered alone. The
least-squares (LS) geometric means for levonorgestrel
AUCss and Cmax,ss were similar across treatments (Table 2;
Fig. 2), with treatment ratios of 105.1 % (90 % CI
97.5–113.2) and 96.8 % (90.4–103.6), respectively. Indi-
vidual AUCss and Cmax,ss ratios (OC plus fostamatinib/OC
alone) ranged from 71.1 to 182 % and from 65.4 to 175 %,
respectively.
Ethinyl estradiol AUCss and Cmax,ss increased when OC
was co-administered with fostamatinib, with geometric LS
mean treatment ratios of 128.2 % (90 % CI 121.1–135.8)
and 134.3 % (90 % CI 126.1–143.0), respectively
(Table 2; Fig. 2). These trends were also observed on an
individual basis, with individual AUCss and Cmax,ss ratios
ranging from 87.8 to 179 % and from 95.3 to 231 %,
respectively.
Table 2 Statistical comparison of primary oral contraceptive pharmacokinetic and pharmacodynamic endpoints following co-administration of
Microgynon 30 (1 tablet/day comprising 30 lg ethinyl estradiol and 150 lg levonorgestrel) and fostamatinib (100 mg twice daily)
Analyte Parameter (units) Treatment n Geometric LS mean Microgynon ? fostamatinib/
microgynon alone
Ratio (%) 90 % CI
Ethinyl estradiol AUCss (ngh/mL) Microgynon alone 27 828.1
Microgynon ? fostamatinib 27 1062 128.2 121.1–135.8
Cmax,ss (ng/mL) Microgynon alone 27 86.2
Microgynon ? fostamatinib 27 115.7 134.3 126.1–143.0
Levonorgestrel AUCss (ngh/mL) Microgynon alone 27 75,970
Microgynon ? fostamatinib 27 79,830 105.1 97.5–113.2
Cmax,ss (ng/mL) Microgynon alone 27 6652
Microgynon ? fostamatinib 27 6439 96.8 90.4–103.6
Progesterone AUCss (nmolh/L) Microgynon alone 27 66.5
Microgynon ? fostamatinib 27 69.4 104.3 96.4–112.9
Cmax,ss (nmol/L) Microgynon alone 27 4.9
Microgynon ? fostamatinib 27 4.9 99.8 90.4–110.1
Sex hormone-binding globulin AUCss (nmolh/L) Microgynon alone 27 2020
Microgynon ? fostamatinib 27 2023 100.1 94.9–105.7
Cmax,ss (nmol/L) Microgynon alone 27 92.6
Microgynon ? fostamatinib 27 92.9 100.4 94.3–106.9
Follicle-stimulating hormone AUCss (IUh/L) Microgynon alone 27 5.6
Microgynon ? fostamatinib 27 4.3 75.6 62.1–92.1
Cmax,ss (IU/L) Microgynon alone 27 0.3
Microgynon ? fostamatinib 27 0.2 76.0 56.2–102.7
Luteinizing hormone AUCss (IUh/L) Microgynon alone 27 4.4
Microgynon ? fostamatinib 27 3.7 83.2 65.5–105.7
Cmax,ss (IU/L) Microgynon alone 27 0.3
Microgynon ? fostamatinib 27 0.2 75.6 51.3–111.6
Results were analyzed by employing a linear fixed-effects model with treatment and subject as fixed effects
AUCss area under the plasma concentration–time curve during the dosing interval at steady state, CI confidence interval, Cmax,ss maximum
plasma concentration at steady state, LS least-squares
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Fig. 2 Mean plasma concentrations of ethinyl estradiol and levonorgestrel, with and without fostamatinib co-administration
Table 3 Statistical comparison of primary R- and S-warfarin pharmacokinetic and pharmacodynamic parameters following co-administration of
warfarin 25 mg and fostamatinib (100 mg twice daily)
Analyte Parameter (units) Treatment n Geometric LS mean Warfarin ? fostamatinib/warfarin alone
Ratio (%) 90 % CI
R-Warfarin AUC (ngh/mL) Warfarin alone 11 65,228
Warfarin ? fostamatinib 11 76,828 117.8 113.0–122.7
Cmax (ng/mL) Warfarin alone 13 1177
Warfarin ? fostamatinib 13 1202 102.1 97.0–107.5
S-Warfarin AUC (ngh/mL) Warfarin alone 14 43,014
Warfarin ? fostamatinib 14 48,528 112.8 107.4–118.5
Cmax (ng/mL) Warfarin alone 14 1188
Warfarin ? fostamatinib 14 1173 98.7 91.5–106.4
INR INRmax Warfarin alone 14 1.65
Warfarin ? fostamatinib 14 1.48 89.7 84.6–95.2
AUCINR,0–168 (h) Warfarin alone 14 206.65
Warfarin ? fostamatinib 14 200.44 97.0 95.3–98.8
Results based on analysis of variance model on log-transformed pharmacokinetic parameters with fixed effects for treatment and subject
AUC area under the plasma concentration–time curve extrapolated to infinity, AUCINR,0–168 area under the INR time curve from zero to 168 h
post-dose, CI confidence interval, Cmax maximum plasma concentration, INR international normalized ratio, INRmax maximum INR, LS least-
squares
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3.2.2 Warfarin Interaction Study
Table 3 compares R- and S-warfarin AUC and Cmax when
warfarin was administered alone and in combination with
fostamatinib.
In the warfarin study, 15 subjects were enrolled. One
subject was prematurely withdrawn from the study on day
8. Subject E0001009 received only one warfarin adminis-
tration on day 1 and no fostamatinib administrations. The
following subjects were excluded from the pharmacoki-
netic analysis set: subject E0001009: no data available;
subject E0001010: pre-dose plasma concentration equaled
5.4 % of Cmax; subject E0001014: AUC not reported due to
high %AUC extrapolated; and subject E0001023: AUC not
reported due to high %AUC extrapolated.
Concomitant administration of fostamatinib with war-
farin slightly increased the R- and S-warfarin AUC values
compared with when warfarin was given alone [treatment
difference 117.8 % (90 % CI 113.0–122.7) and 112.8 %
(90 % CI 107.4–118.5), respectively]. This was consistent
across the majority of subjects, with AUC differences
ranging from 5.0 to 33.0 % for R-warfarin and 0.0 to
36.0 % for S-warfarin.
Geometric LS mean Cmax of R- and S-warfarin was
unaffected when warfarin was co-administered with fos-
tamatinib, with treatment differences of 102.1 % (90 % CI
97.0–107.5) and 98.7 % (90 % CI 91.5–106.4), respec-
tively. On an individual basis, Cmax differences (warfarin
alone to warfarin plus fostamatinib) ranged from -16.1 to
22 % for R-warfarin and from -25.6 to 27 % for S-war-
farin. Trailing mean plasma concentrations were slightly
higher for each analyte for the combined treatment (Fig. 3).
Furthermore, warfarin co-administration with fostamatinib
resulted in an increase in the geometric mean terminal half-
life (tkz) from 50.7 to 57.3’h for R-warfarin and from 34.5
to 40.6’h for S-warfarin.
3.2.3 Statin Interaction Study
A total of 42 subjects participated in the study; there were
21 subjects in each group. All 21 subjects in group A
(rosuvastatin) completed the study per protocol. In group B
(simvastatin), 19 volunteers completed the study and two
volunteers were withdrawn.
When rosuvastatin 20 mg was co-administered with
fostamatinib, an increase in AUC [treatment difference
Fig. 3 Mean plasma concentrations of R- and S-warfarin, with and without fostamatinib co-administration
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195.6 % (90 % CI 177.6–215.3)] and AUCt [197.1 %
(90 % CI 178.8–217.3)] occurred (Table 4; Fig. 4a). An
increase was also observed in Cmax for rosuvastatin
[188.4 % (90 % CI 169.4–209.6)]. This increase in expo-
sure was observed in all subjects, with parameter ratios for
AUC and Cmax ranging from 1.16 to 3.34 %.
Increases in simvastatin acid AUCt and Cmax also
occurred, with treatment differences of 174.2 % (90 % CI
150.0–202.2) and 182.8 % (90 % CI 156.7–213.3),
respectively, when simvastatin was co-administered with
fostamatinib (Table 4; Fig. 4b). This increase in exposure
was observed in all subjects, with parameter ratios for
AUCt and Cmax ranging from 1.03 to 5.35 %. The half-life
of simvastatin acid was reduced by about 1.5 h in the
presence of fostamatinib.
For simvastatin (lactone) itself (40 mg), co-administra-
tion with fostamatinib increased AUC and AUCt, with
treatment differences of 164.1 % (90 % CI 133.1–202.4)
and 170.1 % (90 % CI 137.1–211.0), respectively
(Table 4). The presence of fostamatinib doubled the Cmax
of simvastatin [treatment difference 212.5 % (90 % CI
164.7–274.3)], with a marginal change in tmax. Simvastatin
tkz decreased by approximately 3 h, which was accom-
panied by a net apparent reduction in clearance of 40.3 %.
This increase in exposure was seen in most subjects, with
parameter ratios for AUC and Cmax ranging from 0.389 to
6.52 %.
There were no clear trends between BCRP and
OATP1B1 genotype and exposure to rosuvastatin or sim-
vastatin, measured by either AUC or AUC treatment ratio.
3.2.4 R406 Exposure: All Studies
Generally, R406 exposure was consistent with the admin-
istered fostamatinib dose in each study (Table 5). Over the
12-h dosing interval in the OC study (period 2, day 21), the
R406 steady-state plasma geometric mean Cmax,ss and
AUCss were 812 ng/mL and 5020 ngh/mL, respectively.
During the dosing period in the warfarin study, R406 had a
geometric mean Cmax,ss of 557 ng/mL and AUCss of
4400 ngh/mL.
Only the statin study design allowed for a comparison of
fostamatinib exposure with and without co-administration
(Table 5). In group A, comparison of the mean R406 AUCs
and Cmax when fostamatinib was administered alone with
those for co-administration with rosuvastatin revealed
slight increases, with treatment differences of 109.9 %
(90 % CI 104.4–115.7) and 112.9 % (90 % CI
102.2–124.8), respectively. Subjects in group B also
demonstrated small changes in R406 exposure between
treatment with fostamatinib alone and in combination with
simvastatin. AUCs and Cmax had reported treatment dif-
ferences of 110.7 % (90 % CI 100.8–121.5) and 111.6 %
(90 % CI 98.0– 127.0), respectively, but individual values
Table 4 Statistical comparison of key rosuvastatin, simvastatin, and simvastatin acid parameters following co-administration of rosuvastatin
(20 mg) or simvastatin (40 mg) with fostamatinib (100 mg twice daily)
Analyte Parameter (units) Treatment n Geometric LS mean Statin 1 fostamatinib/statin alone
Ratio (%) 90 % CI
Rosuvastatin AUC (ngh/mL) Rosuvastatin alone 21 93.7
Rosuvastatin ? fostamatinib 21 183.4 195.6 177.6–215.3
AUCt (ngh/mL) Rosuvastatin alone 21 92.2
Rosuvastatin ? fostamatinib 21 181.6 197.1 178.84–217.3
Cmax (ng/mL) Rosuvastatin alone 21 10.6
Rosuvastatin ? fostamatinib 21 19.9 188.4 169.4–209.6
Simvastatin AUC (ngh/mL) Simvastatin alone 21 27.5
Simvastatin ? fostamatinib 19 45.1 164.1 133.1–202.4
AUCt (ngh/mL) Simvastatin alone 21 26.1
Simvastatin ? fostamatinib 19 44.4 170.1 137.1–211.0
Cmax (ng/mL) Simvastatin alone 21 6.5
Simvastatin ? fostamatinib 19 13.9 212.5 164.7–274.3
Simvastatin acid AUCt (ngh/mL) Simvastatin alone 21 12.6
Simvastatin ? fostamatinib 19 22.0 174.2 150.0–202.2
Cmax (ng/mL) Simvastatin alone 21 1.4
Simvastatin ? fostamatinib 19 2.6 182.8 156.7–213.3
Results based on linear model with fixed effects for treatment and subject
AUC area under the plasma concentration–time curve from zero to infinity, AUCt AUC from zero to the time of the last measurable concen-
tration, CI confidence interval, Cmax, maximum plasma concentration, LS least-squares
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did not show a clear pattern of increase or decrease for
either parameter. The half-life of R406 is typically *14 h,
though it was not determined in the current studies.
3.3 Pharmacodynamics
3.3.1 OC Interaction Study
The main pharmacodynamic findings for the OC study are
summarized in Table 2. Progesterone concentrations were
similar across both treatments on day 21. Progesterone
AUCss and Cmax,ss were unaffected by fostamatinib, with
geometric LS mean treatment differences of 104.3 %
(90 % CI 96.4–112.9) and 99.8 % (90 % CI 90.4–110.1),
respectively. Similarly, SHBG concentrations were com-
parable across treatments, and AUCss and Cmax,ss were
unaffected by fostamatinib co-administration, with geo-
metric LS mean treatment differences of 100.1 % (90 % CI
94.9–105.7) and 100.4 % (90 % CI 94.3–106.9),
respectively.
AUCss and Cmax,ss for LH decreased following co-ad-
ministration of fostamatinib with Microgynon 30, with
geometric LS mean treatment differences of 83.2 % (90 %
CI 65.5–105.7) and 75.6 % (90 % CI 51.3–111.6),
respectively. Fostamatinib co-administration also
decreased FSH exposure, with geometric LS mean treat-
ment differences in AUCss and Cmax of 75.6 % (90 % CI
62.1–92.1) and 76.0 % (90 % CI 56.2–102.7), respectively.
3.3.2 Warfarin Interaction Study
AUCINR,0–168 and INRmax trended down during steady-
state fostamatinib co-administration versus warfarin alone
(Table 3), with geometric LS mean treatment differences
of 97.0 % (90 % CI 95.3–98.8) and 89.7 % (90 % CI
84.6–95.2), respectively.
3.4 Safety Assessments
There were no deaths, serious AEs, or severe AEs. Fur-
thermore, co-administration of fostamatinib alongside
investigational medications produced no clinically relevant
changes regarding laboratory measurements, vital signs,
electrocardiogram, or physical examination. The most
frequently reported AEs by preferred term for each treat-
ment in each study are presented in Table 6.
Fig. 4 a Mean plasma concentrations of rosuvastatin, with and without fostamatinib co-administration. b Mean plasma concentrations of
simvastatin acid, with and without fostamatinib co-administration
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3.4.1 OC Interaction Study
Two subjects (6.1 %) withdrew prematurely from this
study because of AEs (gastroenteritis and upper respiratory
infection), one (3.0 %) because of the physician’s decision,
and three (9.1 %) because of a protocol deviation. Eighteen
subjects (54.5 %) reported one or more AE: 16 (48.5 %)
taking OC only and eight (26.7 %) on co-administration
with fostamatinib. Only one AE (gastroenteritis) was con-
sidered potentially treatment related [reported for one
subject (3.3 %) receiving combination treatment].
3.4.2 Warfarin Interaction Study
No discontinuations due to an AE or other significant AEs
were reported. Six AEs were reported for five subjects
(33.3 %).
3.4.3 Statin Interaction Study
Two subjects were withdrawn from the simvastatin group
because of AEs: one of influenza and one increased alanine
aminotransferase, judged moderate or mild in intensity and
not causally related to investigational treatment. There
were no clinically relevant trends observed in the fre-
quency of individual AEs for any treatment.
4 Discussion
It is important to establish whether co-administration of
fostamatinib affects the pharmacokinetics of other drugs
with overlapping metabolic pathways. Patients with RA
often experience co-morbidities that require polypharmacy
[10–13]. Fostamatinib and R406 inhibit a range of proteins,
including BCRP, OATP1B1 (data on file), UGTs, and
CYP3A4 [1], which are integral to the transport and
metabolism of several widely prescribed drugs. The present
studies aimed to determine the influence of fostamatinib
co-administration on the pharmacokinetics of OC, war-
farin, and the HMG-CoA reductase inhibitors rosuvastatin
and simvastatin.
In the OC study, a possible explanation of the observed
increase in ethinyl estradiol exposure is inhibition of
CYP3A4, BCRP, or UGT1A1 by R406. Reduced exposure
to LH and FSH, possibly reflecting reduced secretion of
these hormones, is consistent with the observed increase in
ethinyl estradiol, and there would appear to be no increased
risk of pregnancy due to OC failure. Any increased risk of
thrombotic AEs caused by increased exposure to estrogen
due to co-administration of Microgynon 30 (which con-
tains 30 lg of ethinyl estradiol) with fostamatinib would
appear to be modest, as the exposure to ethinyl estradiol is
less than that following ethinyl estradiol 50 lg.
Table 5 Key R406 pharmacokinetic parameters across OC, warfarin, and statin studies
Study Parameter
(units)










27 5020b – –
Cmax,ss (ngmL) Fostamatinib ? oral
contraceptive
27 812b – –
Warfarin studya AUCss (ngh/
mL)
Fostamatinib ? warfarin 14 4400b – –
Cmax,ss (ng.mL) Fostamatinib ? warfarin 14 557
b – –
Statin study, group A
(rosuvastatin)
AUCs (ngh/mL) Fostamatinib alone 21 5667
Fostamatinib ? rosuvastatin 21 6228 109.9 104.4–115.7
Cmax (ng/mL) Fostamatinib alone 21 790.0
Fostamatinib ? rosuvastatin 21 892.3 112.9 102.2–124.8
Statin study, group B (simvastatin) AUCs (ngh/mL) Fostamatinib alone 19 6056
Fostamatinib ? simvastatin 19 6701 110.66 100.8–121.5
Cmax (ng/mL) Fostamatinib alone 19 876.1
Fostamatinib ? simvastatin 19 977.7 111.6 98.0–127.0
Results based on fixed-effects model with fixed effects for treatment and subject
AUCss area under the plasma concentration–time curve during the dosing interval at steady state, AUCs AUC over the dosing interval, CI
confidence interval, Cmax, maximum plasma concentration, Cmax,ss maximum plasma concentration at steady state, LS least-squares, OC oral
contraceptive
a The OC and warfarin studies did not include fostamatinib-alone treatment phases
b Geometric mean
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In the warfarin study, geometric mean R- and S-war-
farin AUC trended upward with the combination treat-
ment. Even so, the CIs surrounding the fostamatinib-
induced differences for R- and S-warfarin both remained
within the interval for non-significance (90 % CI -20.0
to 25.0). The 18 % increase in R-warfarin AUC could be
attributable in part to the weak inhibitory effects of R406
on CYP3A4 observed in vitro. Furthermore, while quan-
tifiable pre-dose R- and S-warfarin concentrations of less
than 5 % of Cmax pose some minimal bias, the prolonged
tkz (approximately 6 h) suggests that these were unlikely
the sole source of the observed increase in exposure.
There were no differences in the mean Cmax for R- and S-
warfarin. Moreover, the small changes in warfarin phar-
macokinetic parameters did not translate into changes in
INR.
Increases in AUC and Cmax were also demonstrated for
rosuvastatin and simvastatin when co-administered with
fostamatinib. Rosuvastatin is a substrate of the efflux
transporter BCRP, which is responsible for restricting its
absorption to 50 % [24, 31]. Therefore, the interaction is
likely a result of inhibition of intestinal BCRP by fosta-
matinib (R788 and R406), leading to increased absorption
(from 50 to 100 %, i.e., a doubling of AUC); this is
supported by the finding that the distribution and elimi-
nation phases of the pharmacokinetic profiles were paral-
lel, indicating no change to biliary or renal elimination
pathways. Based on predictions using mechanistic static
equations and estimated unbound hepatic inlet concentra-
tion of R406, the observed increase in rosuvastatin expo-
sure is unlikely to be a result of inhibition of OATP1B1
(R value = 1.01). The increase in simvastatin (lactone)
exposure is likely a result of inhibition of intestinal BCRP
by fostamatinib (R788 or R406), but may also in part be
due to inhibition of CYP3A4 by R406, as simvastatin
lactone is a substrate of both [32, 33]. Furthermore, for
some subjects, maximum rosuvastatin and simvastatin
Cmax occurred at the first time point. Therefore, it is
possible that the reported values of Cmax underestimate the
increase in absorption. Statins lower low-density lipopro-
tein cholesterol, and some AEs associated with statins,
such as myopathy, are dose related [34]. Vigilance is
recommended upon co-administration with fostamatinib
due to the increased statin exposure, and clinicians may
consider appropriate monitoring for AEs and/or statin dose
reduction where necessary.
Fostamatinib also increased exposure to simvastatin
acid. Because R406 is unlikely to inhibit OATP1B1
in vivo, the increase in simvastatin acid exposure may be a
consequence of a greater conversion of the lactone to
the acid form as a result of higher simvastatin lactone
concentrations in the presence of fostamatinib, or may be a
result of inhibition of CYP3A4 and/or UGT1A1 by R406.
It is also possible that the increased simvastatin exposure
was related to a decrease in the volume of distribution
secondary to transporter inhibition [35].
In both the OC and warfarin studies, R406 mean con-
centrations and estimated pharmacokinetic parameters
were within a range similar to those previously observed
after fostamatinib 100-mg bid dosing. However, R406
exposures were slightly higher (by &10 %) in the statin
study when fostamatinib was combined with either rosu-
vastatin or simvastatin. The mechanism of these modest
increases in exposure is unknown.
5 Conclusion
Clinical investigation revealed that co-administration of
fostamatinib 100 mg bid with OC increased exposure to
ethinyl estradiol, but not levonorgestrel. Fostamatinib co-
administration did not affect the pharmacokinetics or
pharmacodynamics of warfarin to a clinically relevant
extent, although multiple dosing of fostamatinib resulted in
upward trends in AUC for both R- and S-warfarin. Changes
in statin pharmacokinetics were observed when fostama-
tinib was co-administered with either rosuvastatin or sim-
vastatin: exposure to rosuvastatin, and simvastatin and
simvastatin acid, respectively, was increased. Fostamatinib
exhibits drug–drug interactions when co-administered with
OC, simvastatin, or rosuvastatin, with the AUC of the latter
almost doubling. The action of warfarin is unlikely to be
influenced by co-administration with fostamatinib. Fosta-
matinib was well tolerated in all three studies, with no new
safety concerns identified.
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